|
|
Volumn , Issue , 2013, Pages
|
|
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
ANTINEOPLASTIC AGENT;
CD274 PROTEIN, HUMAN;
CTLA4 PROTEIN, HUMAN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
PDCD1 PROTEIN, HUMAN;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
ADVERSE EFFECTS;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
APOPTOSIS;
CARCINOMA, NON-SMALL-CELL LUNG;
DRUG EFFECTS;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
LYMPHOCYTE ACTIVATION;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PATHOLOGY;
RISK FACTOR;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ANIMALS;
ANTIBODIES;
ANTIGENS, CD274;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
CARCINOMA, NON-SMALL-CELL LUNG;
CTLA-4 ANTIGEN;
HUMANS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
LYMPHOCYTE ACTIVATION;
MOLECULAR TARGETED THERAPY;
PROGRAMMED CELL DEATH 1 RECEPTOR;
RISK FACTORS;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
|
|
EID: 84946221495
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.e280 Document Type: Review |
|
Times cited : (46)
|
|
References (0)
|